UV 1

Drug Profile

UV 1

Alternative Names: UV-1; UV1 synthetic peptide vaccine; UV1 vaccine

Latest Information Update: 24 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Norwegian Radium Hospital; Ultimovacs AS
  • Developer Oslo University Hospital; Ultimovacs AS
  • Class Cancer vaccines; Peptide vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Malignant melanoma; Non-small cell lung cancer; Prostate cancer

Most Recent Events

  • 24 Mar 2017 UV 1 is still in phase I/II trials for Malignant melanoma, Non-small cell lung cancer and Prostate cancer in Norway (Intradermal)
  • 01 Nov 2014 Phase-I/II clinical trials in Malignant melanoma (Combination therapy, Metastatic disease, Inoperable/Unresectable, Late-stage disease) in Norway (Intradermal) (NCT02275416)
  • 12 Sep 2014 Ultimovacs and Oslo University Hospital plan a phase I/IIa trial for Malignant melanoma (Combination therapy, Unresectable, Metastatic disease, Late-stage disease) in Norway (NCT02275416)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top